Ireland's liberal tax code continues to attract drugmakers, but some of the long-term players are cutting back on their extensive manufacturing there. Bristol-Myers Squibb, with plans to lay off about 160 workers at two facilities, can now be added to that list.
The small French pharma Stallergenes expects FDA approval for its new allergy immunotherapy this month, about the same time Merck anticipates word on its own. Stallergenes thinks a double dose of immunotherapy marketing could help both companies capture share in the allergy market.
The success of Australia's HPV vaccination catch-up program has given the country a world-leading trove of real-world data on the effectiveness of Merck's Gardasil. By mining this database, researchers have estimated the vaccine halves the risk of young women developing high-grade cervical abnormalities.
Drugmakers aren't spending as much on speaking fees these days. Some companies--namely Pfizer and Eli Lilly--have slashed physician payments by more than half.
The earnings reports for the biggest of Big Pharma are all in. Bayer reported last week, making it possible to see how they stacked up as they came into the new year. There are no big surprises....
Getting costs down on vaccines is always a big deal to countries like India, and so the government there is putting pressure on GlaxoSmithKline and Merck to give it a break on the human papillomavirus (HPV) vaccines, according to The New Indian Express.
Last week, we heard that Merck's consumer unit was bearing down on a sale, with a price of $10 billion-plus. Now, Reuters sources say the deal could be worth up to $12 billion, with several consumer and healthcare companies in on the hunt.
While talks of a rumored swap between Merck's consumer-goods business and Novartis' animal health and vaccines units have cooled, sources now tell The Wall Street Journal they expect industry heavyweights to put in bids that could surpass $10 billion, and Merck has already received preliminary offers for the business.
The President's Cancer Panel is urging federal and state health authorities to do a better job protecting children from preventable cancers by improving access to the HPV vaccine, which could mean a big bump in sales.
The risks of women developing a blood clot while using certain contraceptives are well known and have spawned thousands of lawsuits and resulted in billions of dollars in payments. Now it is Merck's turn to pony up, with a $100 million settlement that some say lets it off cheap.